Abstract

To the Editor: Psoriatic arthritis affects 20% to 30% of patients with psoriasis; however, little is known about racial and ethnic differences in prevalence.1 Limited knowledge regarding disease manifestations in non-White races is exacerbated by an underrepresentation of non-White participants in clinical trials.2 To determine the extent of underrepresentation, a cross-sectional study was performed assessing differences in patient race and ethnicity in completed phase III clinical trials for biologic agents used to treat psoriatic arthritis.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call